From: Chapter 4, PROCAS: Predicting Risk of Breast Cancer at Screening
Included under terms of UK Non-commercial Government License.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Evans DG, Astley S, Stavrinos P, et al. Improvement in risk prediction, early detection and prevention of breast cancer in the NHS Breast Screening Programme and family history clinics: a dual cohort study. Southampton (UK): NIHR Journals Library; 2016 Aug. (Programme Grants for Applied Research, No. 4.11.)
RR at extremes | Gail | Claus | BRCAPRO/ Ford | TC | BOADICEA | |
---|---|---|---|---|---|---|
Prediction | ||||||
Amir et al.57 validation study ratioa | 0.48 | 0.56 | 0.49 | 0.81 | Not assessed | |
95% CI | 0.37 to 0.64 | 0.43 to 0.75 | 0.37 to 0.65 | 0.62 to 1.08 | Not assessed | |
Personal information | ||||||
Age (20–70) | 30 | Yes | Yes | Yes | Yes | Yes |
BMI | 2 | No | No | No | Yes | No |
Alcohol intake (0–4 units) daily | 1.24 | No | No | No | No | No |
Hormonal/reproductive factors | ||||||
Age at menarche | 2 | Yes | No | No | Yes | No |
Age at first live birth | 3 | Yes | No | No | Yes | No |
Age at menopause | 4 | No | No | No | Yes | No |
HRT use | 2 | No | No | No | Yes | No |
OCP use | 1.24 | No | No | No | No | No |
Breastfeeding | 0.8 | No | No | No | No | No |
Plasma oestrogen | 5 | No | No | No | No | No |
Personal breast disease | ||||||
Breast biopsies | 2 | Yes | No | No | Yes | No |
Atypical ductal hyperplasia | 3 | Yes | No | No | Yes | No |
Lobular carcinoma in situ | 4 | No | No | No | Yes | No |
Breast density | 6 | No | No | No | No | No |
Family history | ||||||
First-degree relatives | 3 | Yes | Yes | Yes | Yes | Yes |
Second-degree relatives | 1.5 | No | Yes | Yes | Yes | Yes |
Third-degree relatives | No | No | No | No | Yes | |
Age of onset of breast cancer | 3 | No | Yes | Yes | Yes | Yes |
Bilateral breast cancer | 3 | No | No | Yes | Yes | Yes |
Ovarian cancer | 1.5 | No | No | Yes | Yes | Yes |
Male breast cancer | 3–5 | No | No | Yes | No | Yes |
OCP, oral contraceptive pill.
Expected over observed cancer ratio (all models assessed underestimated cancer occurrence).
Adapted with permission from Evans and Howell.3 © Biomed Central 2007.
From: Chapter 4, PROCAS: Predicting Risk of Breast Cancer at Screening
Included under terms of UK Non-commercial Government License.
Your browsing activity is empty.
Activity recording is turned off.
See more...